Analytical Data
-
Gene name
PHLDA2
-
简介
PHLDA2 protein regulates placenta growth, potentially through its PH domain, which competes with other PH domain-containing proteins, hindering their binding to membrane lipids. PHLDA2 Protein, Human (His) is the recombinant human-derived PHLDA2 protein, expressed by E. coli , with C-6*His labeled tag.
- Application
-
Species
Human
-
Source
E. coli
-
Tag
C-6*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q53GA4
-
Expression Region
M1-P152
-
Protein Length
Full Length
-
Molecular Weight
14-25 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PHLDA2, or PHLDA2 protein, is a member of the pleckstrin homology-like domain family, implicated in various cellular processes, including apoptosis, proliferation, and differentiation. This protein is particularly interesting due to its involvement in the regulation of cell growth and death, which makes it a potential target for cancer therapy. Studies have shown that PHLDA2 expression is upregulated in several human cancers, suggesting its role as an oncogene in certain contexts. Furthermore, PHLDA2 has been linked to the modulation of the tumor microenvironment, influencing immune responses and metastasis. Despite these insights, the precise mechanisms by which PHLDA2 exerts its effects at the molecular level remain poorly understood. Research on the recombinant form of PHLDA2 allows scientists to investigate its structure and function in detail, enabling the identification of potential interaction partners and downstream signaling pathways. This work not only enhances our understanding of the protein's biological roles but also opens avenues for developing novel therapeutic strategies that target PHLDA2-related pathways in cancer and other diseases. Given the increasing evidence of its clinical relevance, exploring PHLDA2 as a biomarker for diagnosis or prognosis in malignancies further underscores the significance of research in this area.
